Drugs.com New Drug ApplicationsOriginal article
Efzimfotase Alfa Granted Priority Review in the US as Treatment for Patients with Hypophosphatasia Aged 2 Years and Older
BLA Filingefzimfotase alfaPositive
AI Analysis
Summary
Alexion's BLA for efzimfotase alfa has been accepted and granted Priority Review by the FDA for the treatment of hypophosphatasia in patients aged 2 years and older. This represents an expedited regulatory pathway for the rare disease therapy.
Outcome Details
BLA accepted and granted Priority Review by FDA
Importance:7/10
Sentiment:
0.70
priority reviewBLArare diseaseFDAbiologics
Read the original article
Published by Drugs.com New Drug Applications on September 18, 2026 10:09 PM